Home
Conditions
Immune System Diseases

Clinical trial condition

Immune System Diseases

Explore clinical trials studying Immune System Diseases. Study availability and eligibility vary by location and protocol.

35,818 public trials 5,047 recruiting studies

Refine in advanced search Browse all conditions

Immune System Diseases trial results

Recruiting

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

NCT06688331

Conditions: Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +8 more
Locations: Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku Bialystok, Poland

Uniwersyteckie Centrum Kliniczne Gdansk, Poland

Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 Slaskiego Uniwersytetu Medycznego W Katowicach Katowice, Poland

Uniwersytet Medyczny W Lodzi Lodz, Poland

View Trial Details

Recruiting

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414

Conditions: Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a, Asthma, Bronchial Diseases, +19 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Recruiting

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations: University of Michigan Ann Arbor, Michigan, United States

View Trial Details

Recruiting

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

NCT07039422

Conditions: Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +17 more
Locations: Novartis Investigative Site Buenos Aires, Argentina

Novartis Investigative Site Roeselare, West-Vlaanderen, Belgium

Novartis Investigative Site Guangzhou, Guangdong, China

Novartis Investigative Site Dalian, Liaoning, China

View all 25 locations

View Trial Details

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

NCT04879043

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Winship Cancer Institute of Emory University Atlanta, Georgia, United States

Norton Healthcare, Inc. Louisville, Kentucky, United States

Nebraska Cancer Institute Omaha, Nebraska, United States

Mount Sinai, The Tisch Cancer Instutute New York, United States

View all 24 locations

View Trial Details

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

NCT06565689

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Northwestern Chicago, Illinois, United States

View Trial Details

Recruiting

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778

Conditions: Cutaneous T-Cell Lymphoma Refractory, Disease Attributes, Hematologic Diseases, +16 more
Locations: David Geffen School of Medicine at the University of California at Los Angeles Los Angeles, California, United States

View Trial Details

Recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

NCT06461988

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Stanford University Palo Alto, California, United States

View Trial Details

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05052528

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Immune System Diseases

Immune System Diseases trial results

Related conditions